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1 Drug description 
Generic/Brand name/ATC code:  
Pertuzumab/Omnitarg ®, Perjeta®/L01XC13 
Developer/Company:  
Hoffmann – La Roche 
Description:  
Pertuzumab, a recombinant humanized monoclonal antibody, blocks ligand-
initiated intracellular signalling (two major pathways: mitogen-activated 
protein (MAP) kinase and phosphoinositide 3-kinase (PI3K)) by targeting 
the extracellular dimerization domain of the human epidermal growth fac-
tor receptor 2 protein (HER2). By inhibiting receptor protein dimerization 
(i.e. homo- and heterodimerization) the activation of HER signalling path-
ways is interrupted. As a consequence cell growth is inhibited and apoptosis 
induced [1]. 
Due to the unique mechanism of action an enhanced effect on tumour inhi-
bition is expected of pertuzumab in comparison to trastuzumab alone, an-
other HER2 targeted therapy [2] . 
The pertuzumab dosage used in clinical trials is 840 mg initially adminis-
tered as a 60-minute intravenous infusion, followed every 3 weeks thereafter 
by 420 mg administered as a 30 to 60 minute intravenous infusion [3]. Prior 
to administration, HER2 positivity needs to be confirmed. 
2 Indication 
Pertuzumab is indicated for the first-line therapy of metastatic HER2+ me-
tastatic breast cancer (BC). 
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3 Current regulatory status 
Pertuzumab has not been licensed yet by the European Medicines Agency 
(EMA), but market application has been submitted and the drug is currently 
under evaluation by the Committee for Medicinal Products for Human Use 
[4]. 
In the U.S., however, market authorization was granted for pertuzumab by 
the Food and Drug Administration (FDA) in June 2012 [3]  
 in combination with trastuzumab and docetaxel for the treatment of 
patients with HER2+ metastatic BC who have not received prior anti-
HER2 therapy or chemotherapy for metastatic disease. 
4 Burden of disease 
In 2009, about 5,000 women were newly diagnosed with and 1,600 died of 
BC in Austria [5] making BC the most common type of cancer in females. 
More than 80% of all cases occur in women aged over 50 years [6]. Risk fac-
tors associated with the development of BC are age, nulliparity, early men-
arche, genetic factors (e.g. genetic mutations such as of the BRCA1, BRCA2) 
or family history [7, 8]. Prognostic factors are age, menopausal status, tu-
mour stage, histology and hormone receptor status [7].  
The Tumor Node Metastasis (TNM) staging classification is used to deter-
mine the disease stage. This staging system reflects the extent of disease 
which is used to inform treatment management decisions and to determine 
prognosis. Besides the primary tumour, the extent to which the regional 
lymph nodes are involved and the absence or presence of distant metastases 
are taken into account, leading to four main stage groupings (stage I to IV) 
[7]. Metastatic disease corresponds to stage IV. Metastases are most common 
in the bones, liver or the lungs [7] but metastases in the brain have been re-
ported to be more common in patients with HER2+ metastatic BC previ-
ously treated with trastuzumab [9-11]. Besides a higher affinity of HER2+ 
tumour cells for the central nervous system, occurrence of brain metastases 
in this setting might also be caused due to a better control of extra-cranial 
disease and thus by a longer overall survival [11].   
Besides the TNM staging, important factors to determine the best manage-
ment strategy are oestrogen-receptor (ER) and progesterone-receptor (PR) 
status in the tumour tissue, HER2 status, menopausal status, and the gen-
eral health of the patient [8]. Predictive factors for response to hormone 
therapy are a long relapse-free interval, isolated bone and soft tissue in-
volvement, and prior response to endocrine therapy. ER+/PR+ tumours are 
most likely to respond to hormone therapy, but even of them, up to 25% are 
refractory to hormone therapy in the first instance and nearly all tumours 
become refractory at one point [7].  
Metastatic disease at diagnosis is present in less than 10% of women [7] and 
evidence suggests that 20% to 25% of all women diagnosed with BC have 
tumours over-expressing HER2 [12-14]. Due to various methods for deter-
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mining HER2 status it might be the case though that these numbers are 
slightly overestimated and that rather 15-20% overexpress HER2 [15]. How-
ever, applying these estimates to an Austrian context would result in about 
100 women with HER2+ advanced metastatic BC. Median survival of wom-
en with metastatic BC is about 18 to 24 months [8] and only 5 - 10% of 
women survive five or more years [7].  
BC with amplification and over-expression of HER2 are usually more ag-
gressive [7, 14] corresponding to a reduced overall survival (OS) and a short-
ened time to relapse [13] but HER2 status is also used to predict response to 
drugs such as trastuzumab or lapatinib [7].  Additionally, primary resistance 
to endocrine therapy might be associated with HER2 over-expression due to 
a cross-talk between ErbB1/ErbB2 and ER pathways and a link between re-
sponsiveness to chemotherapy and HER2 over-expression might exist [7]. 
5 Current treatment 
Choice of therapy for BC is based on numerous factors like tumour histol-
ogy, axillary node status, hormone and HER2 receptor status, presence of 
metastases as well as patient characteristics including menopausal status, 
age and co-morbidities [12, 16].  
Therapy of HER2+ metastatic BC usually aims at symptom palliation, im-
provement of quality-of-life and extension of  life [8]. Even though surgery 
and radiation therapy are indicated for symptom palliation in selected pa-
tients, the mainstay of therapy is systemic treatment. Treatment options for 
the first-line therapy of HER2+ metastatic BC are: 
 Chemotherapy: for example, anthracyclines or taxanes (e.g. docetaxel) 
either as single agent or as combination chemotherapy or in addition 
to molecular targeted therapies [12].  
 Endocrine therapy: for example tamoxifen, anastrozole or letrozole 
for women with HR+ tumours. 
 Targeted therapies:  
 HER2 targeted therapies: 
 Trastuzumab: preferably in combination with single-agent 
chemotherapy (e.g. paclitaxel, carboplatin, docetaxel) or en-
docrine therapy (in the case of HR+ tumours) but also as 
single-agent.  
 Lapatinib in combination with chemotherapy (i.e. capecit-
abine) or in combination with endocrine therapy for HR+ 
tumours [7, 8, 17].  
 Vascular endothelial growth factor receptor inhibitors: 
 Bevacizumab: in combination with chemotherapeutics 
such as paclitaxel or capecitabine [7, 8, 12, 17]. 
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However, for asymptomatic HR+, HER2+ women with slowly progressive 
disease, and without significant visceral involvement, HER2 targeted thera-
pies in combination with endocrine therapy are recommended. Otherwise, 
HER2 targeted therapies with single-agent chemotherapy (e.g. paclitaxel) 
are indicated. The same regimen is also recommended for HR-, HER2+ pa-
tients [7, 8, 17, 18].   
6 Evidence 
A literature search (Ovid Medline, Embase, Cochrane Library, CRD Data-
base) conducted on the 12th of July yielded 161 references. Of these, only one 
phase III trial [19] was included.   
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title  
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [19-21] 
Study  
identifier 
ClinicalTrials.gov number: NCT00567190, CLEOPATRA trial (=CLinical Evaluation Of Pertuzu-
mab And TRAstuzumab), Other Study ID Numbers: TOC4129g, WO20698 
randomized, double-blind, placebo-controlled, phase 3, multi-centre (204 centres in 25 coun-
tries) 
Design 
Duration  Enrolment: February 2008 – July 2010 
Median follow-up: 19.3 months 
Cut-off date for final analysis: May 2011 
Hypothesis Superiority 
Funding Hoffmann-La Roche 
Intervention 
(n = 402) 
8mg/kg trastuzumab followed by maintenance dose of 6mg/kg every 3 
weeks until disease progression (investigator assessed) or unacceptable 
toxic effects 
+ every 3 weeks docetaxel at a starting dose of 75mg/m2 for ≥6 cycles 
+ pertuzumab at a loading dose of 840mg, followed by 420 mg every 3 
weeks until progression or unacceptable toxic effects 
Treatment 
groups 
Control 
(n = 406) 
8mg/kg trastuzumab followed by maintenance dose of 6mg/kg every 3 
weeks until disease progression (investigator assessed) or unacceptable 
toxic effects 
+ every 3 weeks docetaxel at a starting dose of 75mg/m2 for ≥6 cycles 
+ placebo 
trastuzumab + 
chemotherapy 
commonly used regimen 
for HER2+ metastatic 
BC 
only 1 phase III trial 
included 
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Progression-free 
survival (assessed by 
an independent re-
view facility) 
(primary outcome) 
PFS- IRF time from randomization to the first documented radio-
graphical progressive disease, as determined by the inde-
pendent review facility using current RECIST [22], or death 
from any cause, whichever occurs first 
Progression-free 
survival (investiga-
tor assessed) 
PFS the time from randomization to the first documented ra-
diographic progressive disease, as determined by the inves-
tigator using current RECIST [22], or death from any cause, 
whichever comes first 
Overall survival OS time from the date of randomization to the date of death 
from any cause 
Objective response 
rate 
ORR CR or PR determined by the IRF using current RECIST [22]
on two consecutive occasions ≥4 weeks apart. 
Duration of objec-
tive response [20] 
DOR duration of response is defined as the period from the date 
of initial confirmed PR or CR until the date of progressive 
disease or death from any cause. Tumour responses will be 
based on the IRF evaluations using current RECIST [22] 
Endpoints and 
definitions 
Time to symptom 
progression [20] 
- time from randomization to the first symptom progression
(defined as a decrease of five points in the FACT Trial Out-
come Index - Physical Functional Breast) 
Results and analysis 
Analysis  
description 
It was estimated that the study would have 80% power to detect a 33% improvement in me-
dian progression- free survival in the pertuzumab group (hazard ratio, 0.75) at a two-sided sig-
nificance level of 5%. A pre-specified interim analysis of overall survival was performed at the 
time of the primary analysis of independently assessed progression-free survival. 
Inclusion locally recurrent, unresectable, or metastatic HER2+ breast 
cancer; HER2+ status (centrally confirmed by immunohis-
tochemistry or FISH; measurable disease or non-measurable 
disease; tumour hormone-receptor status was determined 
locally; ≥18 years; left ventricular ejection fraction of 
≥50%; ECOG-PS ≤0 or 1; patients may have received one 
hormonal treatment for metastatic breast cancer adjuvant 
or neoadjuvant chemotherapy with or without trastuzu-
mab before randomization 
Exclusion previous therapy for metastatic breast cancer (other than 
that described above), central nervous system metastases, 
prior exposure to a cumulative dose of doxorubicin that ex-
ceeded 360 mg per square meter of body-surface area or its 
equivalent, a previous decline in the left ventricular ejection 
fraction to less than 50% during or after prior trastuzumab 
therapy 
Characteristics C I 
Females, % 100 100 
Age, yrs 
Median (range) 
 
54 (27 - 89) 
 
54 (22 - 82) 
Analysis  
population 
Race or ethnic group, % 
White 
Asian 
Black  
Other 
 
58 
33 
5 
4 
 
61 
32 
3 
5 
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ECOG PS, % 
0 
1 
≥2 
 
61 
39 
0 
 
68 
31 
1 
Disease type at screening, % 
Nonvisceral 
Visceral 
 
22 
78 
 
22 
78 
Hormone-receptor status, % 
ER+, PR+, or both 
ER- and PR- 
Unknown 
 
49 
48 
3 
 
47 
53 
0 
HER2 status, assessed by IHC, % 
0 or 1+ 
2+ 
3+ 
 
1 
8 
91 
 
1 
12 
87 
HER2 status, assessed by FISH, % 
Positive 
Negative  
Data not available 
 
94 
1 
5 
 
96 
0 
4 
Prior adjuvant or neoadjuvant 
chemotherapy , % 
No 
Yes 
Anthracycline 
Hormone 
Taxane 
Trastuzumab 
 
 
53 
47 
40 
24 
23 
10 
 
 
54 
46 
37 
26 
23 
12 
Treatment group (overall) Control Intervention 
Number of subjects N = 406 N = 402 
PFS (independent) 
Median, months 
95%CI 
 
12.4 
NA 
 
18.5 
NA 
PFS (investigator) 
Median, months 
95%CI 
 
12.4 
NA 
 
18.5 
NA 
Overall survival, % of patients 
with event1 
23.6 17.2 
Descriptive sta-
tistics and esti-
mated variability 
 
 
ORR, % 
CR 
PR 
SD 
PD 
69.32 
4.2 
65.2 
20.8 
8.3 
80.22 
5.5 
74.6 
14.6 
3.8 
                                                             
1 interim OS analysis was performed after 165 events had occurred (= 43% of the prespecified total number for the 
final analysis) 
2 P=0.001 for difference in response rates 
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DOR, months [23] 12.5  20.2 
Time to symptom progression, 
weeks [21] 
Median 
Probability  
 
 
18.4 
59.5 
 
 
18.3 
56.7 
Subgroup analyses Control Intervention 
Prior trastuzumab therapy N = 41 N =47 
PFS, months 10.4 16.9 
Prior therapy without trastuzu-
mab 
N = 151 N = 137 
PFS, months 12.6 21.6 
Overall population Intervention vs Control 
HR 0.62 
95%CI 0.51 – 0.75 
PFS (independent) 
P value  <0.001 
HR 0.65 
95%CI 0.54 – 0.78 
PFS (investigator) 
 
P value  <0.001 
HR 0.64 
95%CI 0.47 – 0.88 
OS1 
P value  0.005 
HR 0.97 
95%CI NA 
Time to symptom progression 
P value  0.72 
Subgroup analyses  
HR 0.62 
95%CI 0.35 – 1.07 
PFS (Prior trastuzumab therapy) 
P value  NA 
HR 0.60 
95%CI 0.43 – 0.83 
PFS (Prior therapy without tras-
tuzumab) 
P value  NA 
HR 0.72 
95%CI 0.55 – 0.95 
PFS (ER+, PR+, or both) 
P value  NA 
HR 0.55 
95%CI 0.42 – 0.72 
Effect estimate 
per comparison 
PFS (ER-, PR-, or both) 
P value  NA 
Abbreviations:  TOI-PFB = Trial Outcome Index - Physical Functional Breast, FACT-B = Functional Assessment 
of Cancer Therapy-Breast, IRF = Independent Review Facility, HR = Hazard ratio, CI = Confidence inter-
val, CR = Complete response, PR = Partial response, SD = Stable disease, PP = progressive disease, ECOG 
= Eastern Cooperative Oncology Group, PS = Performance status, FISH = fluorescence in situ hybridiza-
tion, IHC = Immunohistochemistry, ER = Oestrogen receptor, PR = Progesterone receptor 
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Table 2: most frequent adverse events 
CLEOPATRA trial [19] 
Grade (according to 
CTCAE 3.0) 
Outcome, n (%) C 
(n= 397) 
I 
(n=407) 
Diarrhoea 184 (46.3) 272 (66.8) 
Alopecia 240 (60.5) 248 (60.9) 
Neutropenia 197 (49.6) 215 (52.8) 
Nausea 165 (41.6) 172 (42.3) 
Fatigue 146 (36.8) 153 (37.6) 
Rash 96 (24.2) 137 (33.7) 
Decreased appetite  105 (26.4) 119 (29.2) 
Mucosal inflammation 79 (19.9) 113 (27.8) 
Asthenia 120 (30.2) 106 (26.0) 
Peripheral oedema  119 (30.0) 94 (23.1) 
All grades 
(in ≥25% of patients) 
Constipation 99 (24.9) 61 (15.0) 
Neutropenia 182 (45.8) 199 (48.9) 
Febrile neutropenia 30 (7.6) 56 (13.8) 
Leukopenia 58 (14.6) 50 (12.3) 
Grade ≥3  
(in ≥5% of patients) 
Diarrhoea 20 (5.0) 32 (7.9) 
Deaths due to AE 10 (2.5) 8 (2.0) Other 
AEs leading to treatment 
discontinuation [23] 
NA (5.3) NA (6.1) 
 
The CLEOPATRA trial, a phase III trial, enrolled 808 patients with HER2+ 
metastatic BC who had not been treated for their metastatic disease. The 
combination of trastuzumab and docetaxel in addition to pertuzumab was 
compared to placebo with trastuzumab and docetaxel. About half of the pa-
tients enrolled were HR- and about 50% had received prior adjuvant or neo-
adjuvant therapy. However, only about 10% of patients had received prior 
trastuzumab therapy. 
Independently assessed progression-free survival (PFS), the primary out-
come, yielded a gain in median PFS of 6.1 months (HR = 0.62, p<0.001) for 
patients treated with pertuzumab. Similar results were also found in sub-
groups, including, for example, prior adjuvant/neoadjuvant chemotherapy, 
HR+ as well as HR- receptor-status. Even though the benefit of pertuzumab 
therapy was preserved in the subgroup of patients previously treated with 
trastuzumab, this result was not statistically significant. Also, the difference 
in median PFS was higher in patients not previously treated with trastuzu-
mab (9 months) than in patients previously treated with trastuzumab (6.5 
months). Preliminary results (data not mature yet) for OS showed that fewer 
patients had died in the pertuzumab group than in the control group (I 17% 
vs C 24%). The overall response rate was 80% in the pertuzumab group and 
69% in the control group, in both groups primarily driven by partial re-
sponses. Furthermore, with a median number of 15 treatment cycles per pa-
CLEOPATRA trial 
enrolled 808 patients 
who had not been 
treated for metastatic 
BC 
 
+6.1 months in PFS, 
trend towards improved 
OS, better response 
rates 
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tient in the control group and 18 in the pertuzumab group, duration of re-
sponse was longer in the intervention arm.  
Exploratory results for quality-of-life (only available as abstract) indicated 
similar outcomes for both groups, since 60% experienced deterioration of 
health-related quality-of-life in the pertuzumab group and 57% in the pla-
cebo group [21]. 
The most common adverse event (AE) of any grade in the pertuzumab group 
was diarrhoea (I 67% vs C 46%). Other AEs more frequent in the pertuzu-
mab group were rash or mucosal inflammation, occurring with a difference 
of about 9% points. Grade ≥3 AEs with an incidence of at least 2% points in 
the pertuzumab group comprised neutropenia, febrile neutropenia and diar-
rhoea. Left ventricular systolic dysfunction, a side-effect associated with 
trastuzumab + docetaxel therapy, occurred less often in the pertuzumab 
group (I 4.4% vs C 8.3%).  
6.2 Efficacy and safety - further studies 
No further studies were found for the indication investigated.  
7 Estimated costs 
No cost estimates are available for Austria. In the U.S. though, estimated 
monthly treatment costs for Perjeta® are $5,900 [24]. Assuming an 18 
months therapy, total costs would add up to $106,500. Since the drug has 
been licensed in the U.S. in combination with trastuzumab, additional costs 
accrue (~$4,500 per month). Thus, the calculated costs for 18 months, which 
was duration of treatment in the phase III study, are approximately $188,000 
(≈ € 153,500), not taking into account expenditures for chemotherapy or for 
any supportive therapies. However, it is likely that the price is lower in Aus-
tria.  
8 On-going research 
On ClinicalTrial.gov 4 phase III studies on pertuzumab for metastatic BC 
were identified.  
NCT01120184 (MARIANNE trial): will evaluate the efficacy and safety of 
trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab em-
tansine (T-DM1) with pertuzumab-placebo versus the combination of tras-
tuzumab plus taxane in patients with HER2+ progressive or recurrent lo-
cally advanced or previously untreated metastatic BC (estimated study com-
pletion date: April 2016).  
NCT01572038 (PERUSE trial): will evaluate the safety and efficacy of per-
tuzumab in combination with trastuzumab and a taxane in first-line treat-
only exploratory results 
for QoL – similar results 
for pertuzumab in 
comparison to placebo 
higher grade AEs: 
(febrile) neutropenia, 
diarrhoea 
no price available for 
Austria  
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ment in patients with metastatic or locally recurrent HER2+ BC (estimated 
study completion date: April 2016). 
NCT01026142: will evaluate the efficacy and safety of a combination of tras-
tuzumab and capecitabine with or without pertuzumab in patients with 
HER2+ metastatic BC. The study population consists of female patients, 
whose disease has progressed during or following previous trastuzumab 
therapy for metastatic disease (estimated study completion date: August 
2017). 
NCT01358877: will assess the safety and efficacy of pertuzumab in addition 
to chemotherapy plus trastuzumab as adjuvant therapy in patients with op-
erable HER2+ primary BC (estimated study completion date: August 2024). 
In addition, several phase II trials assess, besides BC, the efficacy and safety 
of pertuzumab for many other cancers such as ovarian cancer, prostate can-
cer, gastric cancer or neuroendocrine cancers.  
No further phase III trials were identified on www.clinicaltrialsregister.eu. 
9 Commentary  
The rational for testing trastuzumab + chemotherapy, the standard regimen 
for the subgroup of women with HER2+ BC, with another HER2 targeted 
agent results from the fact that nearly all tumours progress on trastuzumab 
therapy eventually [25]. Besides non-response in the first place, (in about 
40% of all patients [2, 9]), acquired drug resistance is held accountable [25]. 
Thus, combining trastuzumab with pertuzumab, a drug with a complemen-
tary mechanism of action, might enhance tumour inhibition [2, 26] and 
might be active even in trastuzumab resistant tumours [27]. The dual HER2 
targeted approach, in contrast to pertuzumab only, was chosen since some 
evidence suggested that this combination yields better results than a single 
monoclonal approach [28].  
Pertuzumab in combination with trastuzumab + docetaxel was licensed in 
the U.S. in July 2012 for patients who have not received prior anti-HER2 
therapy or chemotherapy for metastatic disease. In Europe, market applica-
tion has been submitted.  
The FDA’s decision on granting market authorisation in the first-line set-
ting was based on the results of the CLEOPATRA trial, a phase III study 
comprising 808 patients overall [19]. The approval took place under FDA’s 
priority review programme, a programme intended for drugs which offer 
major advances in treatment. Within this trial, PFS, the primary outcome, 
was improved by 6.1 months in comparison to placebo and trastuzumab + 
docetaxel, leading to a risk reduction of 38%. Mature results for OS are not 
yet available, but at the time of the interim analysis there was a difference of 
borderline significance. Response rates were better in the pertuzumab arm. 
In terms of AEs, the most common one of higher grade (i.e. grade ≥3) was 
neutropenia in both groups (I 49% vs C 46%). Other, more frequently ob-
served AEs of higher grades in the pertuzumab group were febrile neutro-
penia and diarrhoea. Left ventricular systolic dysfunction, a side-effect asso-
ciated with trastuzumab therapy, was less frequent in the pertuzumab arm 
pertuzumab under 
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other types of cancer 
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than in the placebo arm. Not (yet?) fully published results for quality-of-life 
suggest that pertuzumab does not exert an additional detrimental effect.   
However, even though the licensed indication in the U.S. excludes patients 
who had been treated with trastuzumab for their metastatic disease, only the 
minority of patients (i.e. 10%) enrolled in the CLEOPATRA trial had been 
previously treated with (neo-)adjuvant trastuzumab, a regimen commonly 
used for HER2+ BC in the adjuvant setting. Thus, the study population dif-
fers to those patients who will be treated in daily practice. Even though a 
pre-planned subgroup analysis (n=88) for these “real” patients demon-
strated a risk reduction (but not statistically significant) in progression 
comparable to that of the overall study population, further research is indi-
cated, to obtain a more precise estimate of the treatment effect in trastuzu-
mab pre-treated patients. This is of further importance since expiration of 
the patent of trastuzumab in mid 2014 would result in reduced treatment 
costs if addition of pertuzumab to trastuzumab offers little or no additional 
benefit in this group of patients. Furthermore, despite the fact that HR+ pa-
tients also profited from pertuzumab therapy in the CLEOPATRA trial, the 
benefit was less pronounced than in HR- patients or in the overall popula-
tion. 
Since pertuzumab is also tested in different clinical settings, (e.g. for 
HER2+ early, inflammatory or locally advanced BC [29]) or in combination 
with other agents (e.g. trastuzumab emtansine or capecitabine [2]) and due 
to the fact that several other new drugs are under investigation for the 
treatment of metastatic BC (e.g. neratinib, afatinib, rapamycin [30]), deter-
mination of the most beneficial agents and combinations as well as charac-
terization of selection criteria and identification of the ideal sequencing of 
available treatment options are needed to optimize treatment of BC.    
Due to a clinically relevant gain in PFS [31] and tolerable side-effects, the 
combination of pertuzumab  + trastuzumab + docetaxel has already been 
incorporated into some guidelines [12]. However, even though no cost esti-
mates are available for Austria yet, evidence indicates that pertuzumab will 
be a costly drug [24], costs which have to be added to those of trastuzumab 
and docetaxel.  
 
 
 
 
 
only 10% of patients in 
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